Status:
COMPLETED
Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With Trauma
Lead Sponsor:
Mundipharma SAS
Collaborating Sponsors:
AXONAL
Exystat
Conditions:
Pain, Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A phase 4 randomised, double-blind study to assess the efficacy and safety of Penthrox® used from the outset in multimodal analgesia, in combination with the standard analgesic protocol used in the de...
Detailed Description
On admission, the patient pain score will be measured using a numerical scale (NRS-11) to verify the eligibility of the patient in the study (NRS ≥ 4). At the time of randomisation, the patient's pai...
Eligibility Criteria
Inclusion
- Men and women aged 18 or older
- Patients (in an emergency, parent or relative) who dated and signed their informed consent to participate in the study
- Patients admitted to the emergency department due to a trauma
- Patients having a pain score ≥ 4 measured using a numerical scale (NRS) at the time of admission to emergency departments.
- Patients having a pain score ≥ 40 measured using the VAS at the time of randomisation.
Exclusion
- Life-threatening conditions requiring immediate admission to the operating theatre or the intensive care unit;
- Impaired consciousness according to the investigator regardless of the cause, including head trauma or drug or alcohol consumption;
- Acute medicinal or alcohol intoxication, according to the investigator;
- Pregnant woman or woman at risk of pregnancy and not using highly effective contraception methods or known lactation;
- Analgesic treatment within 5 hours (8 h for sodium diclofenac) prior to admission, except for paracetamol, which is allowed;
- Treatment with nitrous oxide within 5 hours before presentation at the emergency department;
- Use of analgesics for chronic pain;
- Prior use of Penthrox®;
- Use of an investigational product one month before presentation at the emergency department;
- Hypersensitivity to Penthrox® or any other fluoridated anesthetic;
- History of signs of hepatic lesions after use of methoxyflurane or after anaesthesia by a halogenated hydrocarbon;
- Malignant hyperthermia: Known malignant hyperthermia or patient genetic predisposition or patient or family history of serious adverse reactions;
- Clinical evidence of respiratory depression according to the investigator;
- Clinical evidence of cardiovascular instability according to the investigator;
- Clinical renal or hepatic damage, according to the investigator, pre-existing or known;
- Presence of any other clinical condition that can, according to the investigator's opinion, have an impact on the patient's ability to participate in the study or the results of the study.
- Individuals protected by law
Key Trial Info
Start Date :
May 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2018
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT03798899
Start Date
May 14 2018
End Date
December 20 2018
Last Update
January 10 2019
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Annecy Genevois
Annecy, France, 74374
2
GH Carnelle Porte de l'Oise
Beaumont-sur-Oise, France, 95260
3
Hôpital Avicenne - APHP
Bobigny, France, 93000
4
CHRU Lille
Lille, France, 59037